Latest Information
Below you can access the latest press releases, financial reports, corporate governance documents and more. Please note that some documents may refer to Liminal BioSciences' previous name Prometic Life Sciences Inc.
-
Read PDFLMNL Corporate Presentation September
-
Read ArticleLiminal BioSciences Provides Update on Progress on BLA for Ryplazim® (plasminogen)
The FDA confirmed that the resubmission is a complete, Class 2 response and has provided a Prescription Drug User Fee Act ("PDUFA") target action date of March 5, 2021.
-
Read ArticleLiminal Biosciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference
LMNL announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at The H.C. Wainwright 22nd Annual Global Investment Conference
-
Read ArticleLiminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen)
Liminal, through its U.S. subsidiary Prometic Biotherapeutics Inc., has filed a resubmission of the Biologics License Application (BLA) for Ryplazim® (plasminogen) (Ryplazim®) with the U.S. FDA
-
Press Releases
Read More -
Read PDF
Annual Report 2019
-
Read PDF
Quarterly Report Q3 2019
-
Read PDF
Quarterly Report 2019 Q2
-
Financial Reports
Read Now -
Read PDF
Nasdaq Statement of Corporate Governance Differences
-
Read PDF
Mandate of the Chair of the Board 2020
-
LMNL Share Price
View Now -
Read PDF
CEO Position Description 2020
-
Corporate Governance
Read More -
Loading More...
